Yutaka Maeda

Cincinnati Children's Hospital Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index2.7kcitations87works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(23), Cancer-related molecular mechanisms research(11), Lung Cancer Treatments and Mutations(10), Neonatal Respiratory Health Research(10), Virus-based gene therapy research(6)

Publications87 total

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2025Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2025Open Access
Voices <i>in Molecular Pharmaceutics</i>: Meet Dr. Yutaka Maeda, Who Pioneers New Therapies to Treat Lung Disease
Molecular Pharmaceutics·2025
248 Delivery of full-length CFTR to human airway epithelia via AAV using an intein-based approach
Journal of Cystic Fibrosis·2025
PBAE-PEG based lipid nanoparticles for lung cell-specific gene delivery
2024Open Access
Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer
PLoS ONE·2024Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
Cancer Research·2023· 10 citedOpen Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
2023Open Access
Abstract 1479: FOXA2 induces invasive mucinous adenocarcinoma of the lung in the presence of mutant KRAS
Cancer Research·2023
CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1
EBioMedicine·2022· 39 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Takuya Fukazawa(20), Yoshio Naomoto(16), Jeffrey A. Whitsett(15), Tomoki Yamatsuji(12), Junji Matsuoka(10), Minzhe Guo(9), Iris M. Fink-Baldauf(9), Mary L. Durbin(9), Yan Xu(7), Takeshi Nagayasu(7), Koichi Tomoshige(7), Tomoshi Tsuchiya(6), Frances M. Sladek(6), William D. Stuart(6), Nagio Takigawa(5), Hans Michael Haitchi(4), Akio Kazusaka(4), Shoichi Fujita(4), Gang Chen(3), Susan E. Wert(3)